High-dose digestive enzymes prevent NAFLD after pancreaticoduodenectomy

Reuters Health - 28/09/2020 - The use of high-dose digestive enzymes is associated with a reduced incidence of nonalcoholic fatty liver disease (NAFLD) following pancreaticoduodenectomy (PD) compared with normal-dose enzyme replacement, a randomized, non-blinded clinical trial shows. "Pancreatic exocrine dysfunction leads to impaired nutrient absorption; however, replacement therapy is quite effective for these problems," Dr. Koya Yasukawa of Shinshu University School of Medicine, in Asahi, Japan, told Reuters Health by email. Between 8% and 37% of patients develop NAFLD after PD. One recent study suggested that diminished digestive absorption due to pancreatic exocrine dysfunction is involved in the development of NAFLD after PD. Patients commonly receive a digestive-enzyme preparation after PD to compensate for the reduction in exocrine pancreatic capacity, and one report indicated that NAFLD improved after administration of high-dose pancreatic digestive e...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 28 September, 202021 October, 2020